TBPH Theravance Biopharma Forecast, Technical & Fundamental Analysis
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives... Show more
TBPH is expected to report earnings to fall 317.18% to 23 cents per share on November 10
Q3'26
Est.
$0.24
Q2'26
Missed
by $0.17
Q1'26
Missed
by $0.07
Q4'25
Beat
by $0.15
Q3'25
Beat
by $0.20
The last earnings report on August 10 showed earnings per share of -10 cents, missing the estimate of 5 cents. With 67.95K shares outstanding, the current market capitalization sits at 886.77M.
A.I. Advisor
published General Information
General Information
a developer of small molecule pharmaceutical products
A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with SPRC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then SPRC could also see price increases.
Momentum Indicator for TBPH turns positive, indicating new upward trend
TBPH saw its Momentum Indicator move above the 0 level on August 03, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned positive. In of the 98 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TBPH just turned positive on August 14, 2026. Looking at past instances where TBPH's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TBPH advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 159 cases where TBPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TBPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
TBPH broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. TBPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.061) is normal, around the industry mean (20.457). P/E Ratio (16.423) is within average values for comparable stocks, (27.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.558). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (8.496) is also within normal values, averaging (443.914).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
